Abstract
For Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2) the investigation of the heterogeneity of individual infectiousness becomes important due to the cross reactive immunity of general population. Using a sample of infected population with SARS-COV-2 in close geographical proximity to the initial Severe Advanced Respiratory Syndrome-1 (SARS-1) outbreak, we explored the association between infector’s age and dispersion (or heterogeneity) of individual infectiousness (k) in order to investigate the relatedness with the age of an individual’s capability to disperse SARS-COV-2. Interestingly, we find a negative association between k and increase of infector’s age. Significantly this becomes more evident for the age group of 20-60 years comparing with the infectors with younger age. This raises important immuno-epidemiology concerns for effectiveness of public health measures to contain the disease.
One Sentence Summary Dispersion of Coronavirus Disease-19 in China differed with age.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No special reporting quidelines found according to equator network
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available in the main text or the supplementary materials data file.